Forget This Biotech Stock’s Rally Signals Fresh Jump
NovaGen Therapeutics rockets after a major AI-driven deal, highlighting a rare biotech upside amid a cooling AI market.
Value-oriented index funds offer efficient exposure for retirement accounts. Review 2024 picks and what to check before investing.
24,226 articlesNovaGen Therapeutics rockets after a major AI-driven deal, highlighting a rare biotech upside amid a cooling AI market.
Tech weakness pressured theStreet today, dragging the broader market even as select companies posted government contr...
As Nasdaq volatility surges amid broader market jitters, one sub-$20 tech stock with a near-monopoly in a niche data ...
As AI demand drives Marvell Technology higher, investors debate whether the stock can reach $300 this summer. Here’s ...
In a year of sharp rotation, the Vanguard FTSE DEVELOPED Markets ETF ex US is outperforming the S&P 500—yet the decad...
Traders evaluate the best trading charts march during March 2026, testing charting platforms for real-time data, indi...
A Goldman Sachs trading desk note argues that heavy institutional deleveraging has run its course, suggesting a poten...
Ethereum is sliding again as on-chain data show a widening gap between futures bets and spot demand, with dip buyers ...
Micron sits at the crossroads of AI demand, data-center spending, and cyclical memory trends. This guide explains why...
A major Vanguard growth ETF is underperforming the S&P 500 this year. Here's how concentration in mega-cap tech shape...
NVIDIA signals a potential shift in its OpenAI investment with new discussions about winding down the stake. The news...
Unanimity in board votes can mask risk. A fresh comparison to avalanche safety training shows why dissent matters for...